The following antibodies were used to determine TRAIL receptor membrane expression: TRAIL-R1 (HS101), TRAIL-R2 (HS201), TRAIL-R3 (HS301), TRAIL-R4 (HS402) (all purchased from Alexis) and phycoerythrin (PE -conjugated goat anti-mouse.
Therefore, in these cell lines the ratio of DR4 and DR5 membrane expression might be a more important factor in determining TRAIL sensitivity than the expression of decoy receptors on the membrane.
For experiments to determine TRAIL sensitivity, soluble human recombinant KillerTRAIL™ (Alexis Biochemicals, San Diego) was added at 32 hr after transfection; cells were incubated for an additional 24 hr prior to addition of ATPlite™.
Moreover, the presence of intracellular caspase-8 (Eggert et al, 2001) and antiapoptotic proteins such as c-FLIP (Griffith et al, 1998; Leverkus et al, 2000) and/or activation of the transcription factor NF- κB seem to determine TRAIL sensitivity (Jeremias et al, 1998; Goke et al, 2000; Keane et al, 2000; Bernard et al, 2001; Franco et al, 2001; Oya et al, 2001; Wuchter et al, 2001).
Additionally, it is important to elucidate the molecular components that determine TRAIL-receptor preferences in order to be able to select the best TRAIL agents to potentially treat pancreatic cancer and other tumour types in the future.
R2 values also determined the trail parameters, their interaction and showed unpredictability in the response.
To determine whether TRAIL plays a significant role in tumor rejection, CT26 cells were mixed with IgG control mAb and TRAIL neutralizing mAb, respectively, and injected to syngeneic mice.
We first determine by trail the highest arrival rate that all live video flows can be set to while still meeting the delay targets under both the priority-Exp and priority-Log rules.
To test this hypothesis, we first sought to determine whether TRAIL plays a significant role in CTL-mediated suppression of colon carcinoma metastasis.
To determine what TRAIL receptors transmitted the apoptotic signal, cells were treated with agonistic DR4- and DR5-selective antibodies (Novartis) for 3 and 5 h, for Colo205 and HCT15 cells, respectively.
This might contribute to the increased TRAIL sensitivity of 090 cells; however, further studies will be required to determine whether TRAIL-R upregulation is necessary for TRAIL sensitisation by bortezomib.
